Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olsalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.70 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.70 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | KDR | P35968 | 2/20 | 0.96 |
| ▸ | PDE4A | P27815 | 1/20 | 0.96 |
| ▸ | BLVRB | P30043 | 1/20 | 0.96 |
| ▸ | HTT | P42858 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.82 |
| ▸ | THRB | P10828 | 2/20 | 0.82 |
| ▸ | RECQL | P46063 | 2/20 | 0.82 |
| ▸ | APP | P05067 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | PHLPP2 | Q6ZVD8 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olsalazine SCHEMBL19693100 | 1.00 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL2228872 | 1.00 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL2628413 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29861404 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25118 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25119 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29385751 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29378994 | 0.98 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL5922630 | 0.96 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL28138401 | 0.96 | MEN1 (0.96) | MEN1KMT2AKDRPDE4ABLVRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3953 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567554-B | Gel factor and hydrogel loaded with anti-inflammatory agent as well as preparation methods and application thereof | 中国科学技术大学 | 2025-03-07 | — | — | CN | claimed |
| CN-118286469-B | Preparation method for nonmetallic organic magnetic resonance nano diagnosis and treatment agent | 中山大学·深圳 | 2024-12-20 | — | — | CN | claimed |
| WO-2024234393-A1 | FLEXIBLE INTELLIGENT WOOD HAVING RESPONSE FUNCTION, ACTUATOR, AND MANUFACTURING METHOD | 南京林业大学 | 2024-11-21 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118286469-A | Preparation method for nonmetallic organic magnetic resonance nano diagnosis and treatment agent | 中山大学·深圳 | 2024-07-05 | — | — | CN | claimed |
| EP-4335413-A2 | PROSTHETIC TISSUE VALVES | Cormatrix Cardiovascular, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| CN-117567554-A | Gel factor and hydrogel loaded with anti-inflammatory agent as well as preparation methods and application thereof | 中国科学技术大学 | 2024-02-20 | — | — | CN | claimed |
| WO-2023212179-A2 | THERAPEUTIC COMPOSITIONS FOR SKIN DISORDERS AND WOUND REPAIR | UNIVERSITY OF MIAMI (US) | 2023-11-02 | — | — | WO | claimed |
| CN-217865037-U | Encapsulation equipment is used in production of olsalazine sodium capsule | 南京爱文医药研发有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-217864869-U | Powder metering device is used in production of olsalazine sodium capsule | 南京爱文医药研发有限公司 | 2022-11-22 | — | — | CN | claimed |
| EP-1384479-A1 | Preventing or reducing photosensitivity and/or phototoxicity reactions to antiinfective medications | G.D. SEARLE & CO. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2003088811-A2 | GELSOLIN AS A PROGNOSTIC MARKER OF ARTHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030152566-A1 | Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-08-14 | — | — | US | claimed |
| WO-2003040691-A2 | SOLUBLE CD40L(CD154) AS A PROGNOSTIC MARKER OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| JP-2001525058-A | — | — | 2001-12-04 | — | — | JP | claimed |
| EP-1003501-A4 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM & WOMENS HOSPITAL (US) | 2001-01-17 | — | — | EP | claimed |
| EP-1003501-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1998043630-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |